3D bioprinting for high-throughput screening: Drug screening, disease modeling, and precision medicine applications
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
High-throughput technologies have become essential in many fields of pharmaceutical and biological development and production. Such technologies were initially developed with compatibility with liquid handling-based cell culture techniques to produce large-scale 2D cell culture experiments for the compound analysis of candidate drug compounds. Over the past two decades, tools for creating 3D cell cultures, organoids, and other 3D in vitro models, such as cell supportive biomaterials and 3D bioprinting, have rapidly advanced. Concurrently, a significant body of evidence has accumulated which speaks to the many benefits that 3D model systems have over traditional 2D cell cultures. Specifically, 3D cellular models better mimic aspects such as diffusion kinetics, cell-cell interactions, cell-matrix interactions, inclusion of stroma, and other features native to in vivo tissue and as such have become an integral part of academic research. However, most high throughput assays were not developed to specifically support 3D systems. Here, we describe the need for improved compatibility and relevant advances toward deployment and adoption of high throughput 3D models to improve disease modeling, drug efficacy testing, and precision medicine applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3D bioprinting of tissues and organs
Murphy, S. V., & Atala, A. (2014) · Nature Biotechnology · doi:10.1038/nbt.2958 · Cited by 7,034
Hydrogel: Preparation, characterization, and applications: A review
Ahmed, E. M. (2015) · Journal of Advanced Research · doi:10.1016/j.jare.2013.07.006 · Cited by 5,800
A New Initiative on Precision Medicine
Collins, F. S., & Varmus, H. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500523 · Cited by 5,202
Remodelling the extracellular matrix in development and disease
Bonnans, C., Chou, J., & Werb, Z. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3904 · Cited by 4,367
Reconstituting organ-level lung functions on a chip
Huh, D., Matthews, B. D., Mammoto, A., Montoya-Zavala, M., Hsin, H. Y., & Ingber, D. E. (2010) · Science · doi:10.1126/science.1188302 · Cited by 4,250
The Extracellular Matrix: Not Just Pretty Fibrils
Hynes, R. O. (2009) · Science · doi:10.1126/science.1176009 · Cited by 3,527
The third dimension bridges the gap between cell culture and live tissue
Pampaloni, F., Reynaud, E. G., & Stelzer, E. H. K. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2236 · Cited by 2,817
Hydrogels as extracellular matrix mimics for 3D cell culture
Tibbitt, M. W., & Anseth, K. S. (2009) · Biotechnology and Bioengineering · doi:10.1002/bit.22361 · Cited by 2,727
A 3D bioprinting system to produce human-scale tissue constructs with structural integrity
Kang, H.-W., Lee, S. J., Ko, I. K., Kengla, C., Yoo, J. J., & Atala, A. (2016) · Nature Biotechnology · doi:10.1038/nbt.3413 · Cited by 2,622
Printing three-dimensional tissue analogues with decellularized extracellular matrix bioink
Pati, F., Jang, J., Ha, D.-H., Won Kim, S., Rhie, J.-W., Shim, J.-H., Kim, D.-H., & Cho, D.-W. (2014) · Nature Communications · doi:10.1038/ncomms4935 · Cited by 1,904
Cited by
3D bioprinting for reconstituting the cancer microenvironment
Datta, P., Dey, M., Ataie, Z., Unutmaz, D., & Ozbolat, I. T. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-0121-2 · Cited by 304
Maloney, E., Clark, C., Sivakumar, H., Yoo, K., Aleman, J., Rajan, S. A. P., Forsythe, S., Mazzocchi, A., Laxton, A. W., Tatter, S. B., et al. (2020) · Micromachines · doi:10.3390/mi11020208 · Cited by 161
“However, being able to scale up, automate, and improve the consistency of these PTOs is a hurdle [43].”
BackgroundSelf-citationDrug screening at single-organoid resolution via bioprinting and interferometry
Tebon, P. J., Wang, B., Markowitz, A. L., Davarifar, A., Krawczuk, P., Murray, G., Nguyen, H. T. L., Tavanaie, N., Nguyen, T. L., Boutros, P. C., et al. (2021) · doi:10.1101/2021.10.03.462896 · Cited by 155
A critical perspective on 3D liver models for drug metabolism and toxicology studies
Serras, A. S., Rodrigues, J. S., Cipriano, M., Rodrigues, A. V., Oliveira, N. G., & Miranda, J. P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.626805 · Cited by 138
Yee, C., Dickson, K.-A., Muntasir, M. N., Ma, Y., & Marsh, D. J. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.836984 · Cited by 66
“…laser-assisted bioprinting or stereolithography with ovarian cancer cells, these are promising techniques that could enable high-throughput 3D ovarian cancer cell model development that would seamlessly integrate with existing high-throughput drug screening technologies (Mazzocchi et al., 2019).”
BackgroundThe future of skin toxicology testing–three-dimensional bioprinting meets microfluidics
Ng, W. L., & Yeong, W. Y. (2019) · International Journal of Bioprinting · doi:10.18063/ijb.v5i2.1.237 · Cited by 48
Lou, X., Zhou, Q., Dong, Z., Bai, L., Su, J., & Yue, H. (2025) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2025.07.010 · Cited by 17
“A rational integration of these parameters is critical to ensuring structural stability, functional maturation, and long-term viability of bone organoids in vitro , thereby enhancing their utility in disease modeling, drug screening, and regenerative medicine applications [49,50].”
Metadata
- Authors
- Mazzocchi, A., Soker, S., & Skardal, A.
- Venue
- Applied Physics Reviews
- Publisher
- AIP Publishing
- Published
- 2019-02-06
- Volume
- 6
- Issue
- 1
- ISSN
- 1931-9401 (ISSN-L)
- OpenAlex
- W2914997530
- Cited by
- 168
- References
- 35
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.